Dr. Peter Martin Explains a Trial Testing the Combination of Ibrutinib + Palbociclib for Patients with Previously Treated Mantle Cell Lymphoma

In this video Dr. Peter Martin explains the benefits of a recently opened phase I trial of ibrutinib plus palbociclib for patients with previously treated mantle cell lymphoma (MCL). The trial will evaluate the safety and activity of the combination. This is a Weill Cornell Medical College investigator-initiated clinical trial, sponsored by the Cancer Therapy Evaluation Program at the National Cancer Institute.

If you’re interested in participating in this trial please call 646-962-2074 for more information.

Author: lymphomaprogram

Located on the Upper East Side of New York City, the Lymphoma Program at Weill Cornell Medical College/NewYork Presbyterian Hospital is internationally recognized for our efforts to enable patients with non-Hodgkin lymphoma, Hodgkin disease and related disorders to have the best possible clinical outcome, including cure when possible.

Post a Comment

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s